SYDNEY WORD: Open Payments
NPI 1760122162 · RUSSELLVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$444 in 28 payments from 11 companies in 2025. Trend: 2023 $158 · 2024 $371 · 2025 $444
Food & beverage: $444
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $136 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| ABBVIE INC. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| Cranial Technologies, Inc | 1 | $14 |
Products named: CAPLYTA, XIFAXAN, REXULTI, FANAPT, QULIPTA, VRAYLAR, VOQUEZNA, ARISTADA.
Industry payments across KY — which companies pay providers there.
